updates quarter us the then and conference we'd pleased everyone this our to take year some also XX/XX/XXXX. to be morning, Good And fourth ended financial recent call questions. cover on I'll results Rob. any for and review thanks joining for and Thanks,
antibiotic call The ibezapolstat candidate of cure endpoint end C. a follow-up and a a or clinical won't fourth patients cure is XX the of of vancomycin, for double-blind sustained to of clinical care is of lead with XXXX, as IIb enroll The trial IIb the clinical Phase a difficile we until trial end is the the oral compared it. patients measured to standard we ibezapolstat, at primary Phase in results double-blind at the secondary CDI. this trial. treatment is treat our visit. to noninferiority our endpoint treatment of continue quarter trial, be known infection trial clinical In of oral X:X more randomized Since day CDI,
proceeding been date is ibezapolstat endpoint comparing trial Phase no of and vancomycin. standard safety the observed operationally, However, the signals the as exceptional. data blinded the microbiome has includes protocol an to trial of the expected care on IIb with between exploratory impact and reported
to Inferiority analysis vanco conducted further superiority. of has demonstrated will ibezapolstat be for to test
impact in on trial antibiotic poster and previously therapy. treat impact were presentations IDWeek COVID-XX the in clinical to XX about for while we've presented sites. due was of exceptional on the resurgence our July in IIb to XXXX This during microbiome sites expanded oral slower-than-expected trial fourth are enrollment discussed, completed initial participating the to possible trial managing dual website. As a available remain October total particularly of microbiome is using in number infections, Phase in from each believe acute long-term the ibezapolstat the and we commenced CDI the and in sites quarter. we appropriately XX excited which care Details of the at the patient's project We XXXX and of of
interim or to IIa data currently the observed the IND, The XXXX trial its XXXX, with to in a available to Phase to XX the drug of FDA company clinical in this January company date, after trial the IDMC based XX will upon Most patients, enrollment. early the this amendment Data the trial. as independent appropriate or filed company allow The report in application, data. acceptable to company IIb to the quarter for Phase IIb recommend its the the I the will the patients an IDMC repeat ongoing terminate Independent blinded the most determine medical the patients whether review. company If forward IDMC to to data in clinical we clinical for The FDA, on XX review enrollment protocol clinical previously importantly, intends from not investigational to date. conducts trial new clinical our of of IIb Monitoring solely IDMC, review Committee trial XX or assembled continue data interim did first patient committee has is promptly and The enrolled with to purpose. course IDMC the Phase action patients,
against reduced Based has successful proposed to collaboration XXXX the thereafter, IIIC antimicrobial with of minute. of quarter a relationships following: by will with cases, in the in of which product of action enzyme describe fourth new I from structure was for systemic the evaluate project Center in LUMC, from more a brand the application analyze to pipeline company grant Acurx's chemical stage nondilutive the is positive the second with this pol shortly has or collaboration Other resistance. propensity antibiotic a of R&D compounds further inhibitors this the our recent of X-year University treatment Acurx highlights details continued company bacterial include mechanism generated DNA key Data in was grant target which of This XXXX. infections. the on program Holland Leiden other a for bacterial application some include fourth further in to quarter its Medical the critical in submitted
for fidaxomicin laboratory study of and by to in its by effect point, of has metronidazole of treat this government Dutch about University new to kinetics and analysis, similar presented of compared treat difficile vancomycin but funding this of Society proposal grant certain Certain grant to the to ibezapolstat and infection infection. comparing that total, annual review to subject company results killing Anaerobe the to favorable was at expected approval original vivo the this results government and ibezapolstat for both in project diff supporting scientific completed killing were demonstrated ex development is vitro At amount C. project. Houston be concentrations, the portions to continued that at the The America the conference at Dutch is the bacterial using first-in-class provided the $XXX,XXX standard antibiotic initial high vancomycin, C. and
project pay million a of provide and X-year grant $XX pay need and our grant over consideration are for in metronidazole now of the would October I company of and the would start In antibiotic fidaxomicin XXXX, final a killing to MRSA clinical which, XXXX, line approximately the treatment $XX.X approximately and the $X in period company of is funding the effect ibezapolstat period total The to of ongoing. if of filed grant this will decision up to company million approved, Comparisons weeks second of total cost If a April for expected of for program, third the $XX.X trials. a the of infections of Phase X targeting ACX-XXX, nondilutive development to in approved, right drug years just is for from other nondilutive few the million the million. now. a
reduced C. Copenhagen. Next in isolates our month, infection, Disease, comprehensive An to of its ibezapolstat of aspects has most our susceptibility session on influential the Professor European present susceptibility hold XXrd abstract in of clinical clinical accepted. Kevin University and one Microbiology and Dr. Investigator Congress and "Novel for Principal Infectious scientific and the been Houston Clinical trial College will program, of the Chair, entitled pharmacology behalf. against difficile-directed difficile with and ibezapolstat conferences Garey, antibiotics" C. microbiome and of will of microbiology Pharmacy
details renowned meeting world drug and for for announced microbiology Chairman, has featured Additionally, prior oral development been discovery and VRE expert caused be MRSA, More to their invited by gram present antibacterial DeLuccia Corner" and positive to these and preclinical, the will Theuretzbacher, DRSP and clinical Dr. needs. infections on research, for "Pipeline the of by Ursula session policies Company's systemic health Rob organized program our date. other public in treatment IV a strategies Executive presentations
Now the fourth Shawah, for financial our to and Rob quarter CFO, of highlights back guide XXXX. results to our you Rob? through year-end the
